Demographic shifts in the population have meant that the number of older adults in society has expanded hugely; the population aged over 60 years worldwide is predicted to rise from 841 million in 2013 to more than 2 billion by 2050 1 . Musculoskeletal disease places a substantial burden on the ageing population, contributing 7.5% of the disease burden in those over 60 years of age 2 . The development of both osteoporosis and sarcopenia in later life is a common problem encountered as part of musculoskeletal ageing, and contributes substantially to this burden on both personal and societal levels 3, 4 . Research into sarcopenia has perhaps been hampered by uncertainty regarding how best to define the condition 4 ; indeed, the very term sarcopenia, derived from Greek meaning 'loss of flesh' , was only suggested in 1989 (REF. 5), and the concept of loss of muscle function as well as muscle mass with age has since been incorporated in the past decade. However, controversy remains as to how best to define this condition.
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Muscle mass and strength peak in early adulthood , followed by a gradual decline after the age of 40 years 6 , then a more substantial decline from the fifth decade onwards 7 (FIG. 1) . Total muscle mass decreases by nearly 50% between the ages of 20 years and 90 years 7, 8 . Lifestyle factors have an important role in the prevention of sarcopenia. Adoption of a more sedentary lifestyle among the general population coupled with an extended life expectancy suggest that the prevalence of sarcopenia and associated health consequences will become more common in years to come.
Sarcopenia is associated with a number of adverse outcomes including falls, fractures, frailty and mortality 3 . Impaired physical function (but not multimorbidity) is predictive of mortality in older community-dwellers, as shown by results from the ilSIRENTE prospective cohort study 9 . The physical frailty phenotype operationalized by Fried et al. 10 is defined as patients possessing three or more of the following criteria: weakness (assessed by grip strength), slowness (assessed by gait speed), low levels of physical activity, low levels of energy (self-reported) and unintentional weight loss. This phenotype predicts many of the negative outcomes described above for sarcopenia, and indeed muscle loss is thought to be the mediator of this association. Given the interconnection between sarcopenia and frailty, the emergence of a large amount of literature from studies designed to identify strategies 1, 3, 4, 5, 6 and Cyrus Cooper 1, 7 Abstract | Musculoskeletal ageing is a major public health concern owing to demographic shifts in the population. Sarcopenia, generally defined as the age-related loss of muscle mass and function, is associated with considerable risk of falls, loss of independence in older adults and hospitalization with poorer health outcomes. This condition is therefore associated with increased morbidity and health care costs. As with bone mass, muscle mass and strength increase during late adolescence and early adulthood, but begin to decline substantially from ~50 years of age. Sarcopenia is characterized by many features, which include loss of muscle mass, altered muscle composition, infiltration with fat and fibrous tissue and alterations in innervation. A better understanding of these factors might help us to develop strategies that target these effects. To date, however, methodological challenges and controversies regarding how best to define the condition, in addition to uncertainty about what outcome measures to consider, have delayed research into possible therapeutic options. Most pharmacological agents investigated to date are hormonal, although new developments have seen the emergence of agents that target myostatin signalling to increase muscle mass. In this review we consider the current approaching for defining sarcopenia and discuss its epidemiology, pathogenesis, and potential therapeutic opportunities.
to prevent the progression of these twin pathologies is not surprising. Perhaps inevitably, this literature presents the case for the use of biomarkers to identify those at greatest risk, although to date no single biomarker has been identified 11 . In this Review we consider the current definitional approaches to sarcopenia and discuss the epidemiology and pathogenesis of the condition as well as possible therapeutic advances in its treatment.
Defining sarcopenia
Considerable debate is ongoing regarding the best approach for defining sarcopenia, owing in part to the different technologies available to inform any definition (for example, dual-energy X-ray absorptiometry or bioimpedance analysis). A particular criticism of defining sarcopenia on the basis of muscle mass (as has historically been the case) is that although loss of muscle strength and muscle mass are frequently correlated, loss of muscle strength often exceeds muscle loss. A number of international bodies have contributed to the debate regarding how best to define the condition (TABLE 1) , including the International Osteoporosis Foundation (IOF), the European Society for the Clinical and Economic Aspects of Osteoarthritis and Osteoporosis (ESCEO) and the Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. A report from the FNIH using data from nine sources of communitydwelling older persons from the USA, Iceland and Europe highlights numerous priorities for sarcopenia research 8 . In particular, the report looks at evaluating the effect in the clinic of applying a clinical definition that requires few tests, epidemiological data reporting rates of change in lean mass over time and interventions that might retard muscle loss (such as lifestyle and pharmacological interventions). Cut-off points for grip strength similar to those used in the FNIH study 8 (<27 kg in men, <16 kg in women) were used in another study 12 that described grip strength over an adult's life by using normative data from 12 UK studies (49,964 participants), work triggered by a growing understanding of the early developmental origins of sarcopenia 13 . One of the latest contributions to the debate surrounding definitional approaches to sarcopenia has come from the Asian Working Group for Sarcopenia, which has produced recommendations for cut-off values for muscle mass measurements, handgrip strength and usual gait speed 14 . Taken together, the latest literature suggests that there is great motivation worldwide to develop a definition of sarcopenia that can be used in clinical and research settings.
Epidemiology and outcomes
Current definitions of sarcopenia are only newly developed and still not fully accepted. Varying approaches to defining sarcopenia (such as those described in TABLE 1) inevitably affect its estimated prevalence. Estimates range from 10% in individuals >65 years of age 3 , rising to 30% in men over 80 (REFS 3, 15) . Applying the European Working Group on Sarcopenia (EWGSOP) definition of sarcopenia in a community-dwelling population (the UK-based Hertfordshire Cohort Study), researchers reported that sarcopenia was present in 4.6% of men and 7.9% of women at a mean age of 67 years 16 . Unlike for osteoporosis, where the obvious outcome is a fragility fracture, an outcome associated with sarcopenia that is important and quantifiable in terms of public health is much harder to define. One important outcome to consider is loss of independence, which might be a consequence of a loss in reserve capacity, defined as the level of resources possessed by an individual for responding effectively to challenging conditions. In the neuromuscular system, a 30% reduction in reserve capacity limits its normal function, and a loss of 70% results in system failure 17 . Previous studies have illustrated that sarcopenia in older men and women predicts loss of independence in activities of daily living 18, 19 ; for example, loss of the ability to walk (which might be associated with sarcopenia) is linked to increased healthcare costs 20 , and sarcopenia is associated with a higher risk of falling, which leads to loss of independence and hospitalization costs 21 . Sarcopenia is also a predictor of poor outcomes in patients who are undergoing surgery or have other serious comorbidities [22] [23] [24] .
One of the few studies that have attempted to estimate the economic costs associated with sarcopenia in any country reported a direct cost of approximately $18.5 billion ($10.8 billion in men and $7.7 billion in women) in the USA in 2000, accounting for ~1.5% of the country's total health expenditure 25 ; these costs are incurred by hospitalization, nursing home admissions
Key points
• Sarcopenia, the age-related loss of muscle mass and function, is associated with considerable morbidity and health care costs • Approaches to defining sarcopenia remain controversial, although several groups have proposed ways of defining the condition • Moderate-quality evidence suggests that exercise interventions improve muscle strength and physical performance in patients with sarcopenia, whereas the benefits of nutritional interventions are more equivocal • Most pharmacological agents for sarcopenia investigated to date are hormonal (testosterone and selective androgen receptor modulators) although therapies targeting myostatin signalling are emerging as new developments
Author addresses
1 Nature Reviews | Rheumatology and home-based health care expenditure. An important research goal, in the USA and elsewhere, is to provide up-to-date estimates of the costs associated with sarcopenia, perhaps also attempting to quantify the indirect costs, such as home-based health care, outlined above. Given that sarcopenia might also be associated with other health care costs, such as lack of productivity, reduced quality of life and psychological problems, research in this area is also timely, especially with the development of a quality of life questionnaire specifically designed for use in patients with sarcopenia 26 .
Aetiology of sarcopenia
Muscle cells are probably influenced by the same fundamental processes of ageing that affect all living cells. These processes include replicative senescence (a limitation in the number of times that cells can divide) and impaired stem cell regeneration, accumulation of cell damage, reduced autophagy (clearance of cell damage) and reduced mitochondrial energy generation. A full discussion of the biology of ageing as applied to muscle is outside the scope of this Review, and has been reviewed elsewhere [27] [28] [29] [30] . However, research into the aetiology of age-related muscle loss is important to the development of therapeutic strategies to retard or prevent muscle loss 31 . Sarcopenia involves negative protein turnover, characterized by a reduction in myofibrillar and mitochondrial protein synthesis 27 . Because mitochondria are important in energy provision, redox homeo stasis and regulation of cell death, many articles over the past 5 years have focused on age-related alterations in mitochondrial function and their role in the aetiology of sarcopenia. For example, one review 28 postulates that defective redox signalling might be important in reducing the integrity of the ageing neuro muscular system, and that a better understanding of the causes of defective mitochondrial homeostasis provides an opportunity to identify targeted interventions. Another review, published in 2016 (REF. 29 ), highlights the progressive reduction in the regenerative capacity of the skeletal muscle stem cells (called satellite cells), which are critical for muscle repair in response to trauma or damage. Decreased capacity for muscle regeneration and increased apoptosis in muscle might have an important role in sarcopenia aetiology, an assertion supported by the observation that apoptotic signalling correlates with slow walking speed and reduced muscle volume 30 . Loss of muscle strength 32 and neuromuscular impairment (through loss of motor units and loss of motor neurons) accompanies skeletal atrophy with ageing. Finally, a better understanding of the interplay between satellite cell extrinsic and intrinsic factors in sarcopenia might reveal therapeutic opportunities 33 . Systemic inflammation might also be important in the pathogenesis of muscle loss in later life; for example, increased production of proinflammatory cytokines could affect the mechanisms outlined above. Age-related inflammation (also referred to as 'inflammaging' ,) first proposed as a phenomenon in 2000 (REF. 34 ), is a possible underlying cause of muscle loss. Inflammaging is thought to result from a lifetime of exposure to both clinical and subclinical infections, as well as to exposure to non-infective antigens, leading to a high antigenic load 35 . The inflammatory response to this antigenic load leads to tissue damage and the production of reactive oxygen species, resulting in the release of additional cytokines 36 . This vicious cycle favours a chronic proinflammatory state 37 , but might be amenable to therapeutic manipulation 38 .
Risk factors for sarcopenia Just as for bone loss, factors that affect muscle can do so from an early age by influencing the development of peak muscle mass and/or rates of muscle loss. For instance, peak muscle mass is attained in youth but could be a determinant of function later in life and is influenced by both genetic and environmental factors. As an example, grip strength over the life course is illustrated in  FIG. 1 . Genetic and environmental factors are also major determinants of muscle strength, and are potentially amenable to modification. For example, lifestyle factors, such as those displayed in FIG. 2 , can influence muscle mass in later life. Comorbidities are common in older adults, and might coexist with, or contribute to, loss of muscle mass and function. Pharmacological intervention, for example with corticosteroid therapy, in patients with comorbidities such as polymyalgia rheumatic might also contribute to muscle loss.
Body composition
An individual's body weight and composition is one risk factor to consider. With increasing age, and individual's proportion of body fat increases and muscle mass decreases, which can result in a stable body weight but altered body composition. The term sarcopenic obesity describes a condition wherein sarcopenia and obesity coexist, resulting in a disproportionate amount of fat mass relative to lean muscle mass. The estimated prevalence of sarcopenic obesity ranges from 0% to 41% in older populations, owing to the varying definitions of both sarcopenia and obesity 39 . However, these two conditions might share common aetiologic pathways; for example, both show an accompanying increase in adipokines and inflammation that might adversely affect muscle quality 40 . Further research into sarcopenic obesity is important, as highlighted in the review by Cauley et al. 39 . Although obese or overweight adults often have a higher muscle mass compared with nonobese adults, their muscle quality and functional status is lower 41 . This could be a reflection of the common pathways involved in the development of sarcopenia and obesity, which might have additive effects on the development of adverse health consequences associated with both conditions; for example, raised adipokines in obesity could negatively affect muscle quality. Substantial weight loss has been associated with loss of grip strength, although coexisting comorbidities could be a confounding factor 42 .
Physical activity is well known to affect muscle mass and strength. Inactivity leads to loss of muscle mass and strength, irrespective of age; during extended bed rest muscle strength decreases before the subsequent decrease in muscle mass is observed 43 . By contrast, lifelong physical exercise preserves muscle structure and function 44 . Specifically, the risk of mobility impairment in older adults decreases with increased mid-life leisure time physical activity, although, conversely, occupational activity might actually have the reverse effect 45 . A systematic review in 2014 also highlighted the studies that have suggested benefits for exercise on muscle health in later life 46 . Law et al. 47 also provide an overview of the evidence for the role of resistance exercise in the prevention and treatment of sarcopenia, highlighting certain critical factors (namely exercise intensity, volume and progression) that are key to optimizing the resistance exercise prescription.
Diet and smoking
Cigarette smoking might have direct effects on muscle, as well as being associated with other detrimental lifestyle factors. For example, the MINOS study 48 demonstrated that current smokers have lowered appendicular muscle mass compared with non-smokers, results that showed a dose-effect relationship. However, other studies have reported no such association 49 . Alcohol consumption might also affect muscle health. Although the MINOS study found no association between muscle mass and moderate alcohol intake 48 , one might speculate that heavy consumption of alcohol could conceivably lower muscle mass via effects on nutrition, physical activity and hormone levels 50 . However, moderate alcohol consumption does not seem to be harmful to muscle 51 . Dietary factors might also have a role in maintaining muscle mass and strength. Poor nutrition or reduced physical activity in older people reduces their rate of muscle protein synthesis by 30%, independent of ageing itself, an observation that is particularly evidence with mitochondrial protein synthesis in human skeletal muscle [52] [53] [54] [55] . Multiple studies have demonstrated a positive association between protein intake and preservation of lean bone mass in older adults 56, 57 ; however, past studies of protein supplementation, most of which used a combination of supplementation and resistance training, have shown mixed results 58 . Vitamin D status is thought to be relevant to all areas of musculoskeletal ageing; low vitamin D levels are associated with poor balance and with an increased risk of falls 59 . A raised parathyroid hormone level often accompanies low vitamin D levels and is also associated with sarcopenia and the risk of falling independently of vitamin D status 60 . Given the above findings, a review from the ESCEO included dietary recommendations for the prevention of age-related deterioration of the musculoskeletal system, including optimal intake of dietary protein and vitamin D 53 . However, a systematic review published in 2014 reported moderate quality evidence that exercise interventions improve muscle strength and physical performance whereas the benefits of nutritional interventions were more equivocal 61 . Further research is required to determine which of these factors is predominant in the development of sarcopenia.
Pharmacological therapy
The management of any common health problem typically includes two possible approaches; identification of individuals at high risk of having, or developing the condition (in this case those with sarcopenia or presarcopenia) or trying to improve the general health of the whole population through lifestyle measures (in the case of sarcopenia, these might include dietary intervention and physical activity). Drugs designed to treat sarco penia are now starting to emerge. When considering the patients selected to enter studies of novel therapies to prevent or retard development of sarcopenia, it is helpful to be aware of the industry regulatory processes surrounding drug development. The IOF have published recommendations specifically addressing the conduct of sarcopenia clinical trials, and suggest possible trial endpoints and selection criteria for individuals who might participate in such studies 62 . These recommendations highlight the notion that prevention of sarcopenia in high-risk pre-sarcopenic individuals could be possible, as might the treatment of individuals in whom sarcopenia has already developed. Therapeutic targets for the treatment of sarcopenia might include components of the anabolic and catabolic signalling pathways, some of which are currently under investigation (TABLE 2) .
Hormonal manipulation has formed the basis of many of the therapies for sarcopenia investigated to date. Supplementation with testosterone increases skeletal muscle volume by promoting hypertrophy of myofibres 63 ; however, testosterone is also associated with notable adverse effects and whether its benefits translate to improved muscle function has not been clearly demonstrated in clinical trials. Atkinson et al. demonstrated that in pre-frail and frail elderly men, daily treatment with a transdermal testosterone gel (50 mg) increased testosterone levels from 11.6 nmol/l (SD 3.5 nmol/l) to 18.0 nmol/l (SD 8.1 nmol/l), and preserved muscle thickness, whereas a decreased muscle thickness was observed in the placebo group 63 . In phase II trials, treatment with the selective androgen receptor modulator (SARM) enbosarm resulted in a dose-dependent increase in total lean body mass, in addition to improvements in physical function, in both male and female participants in their seventh decade 64 . Furthermore, administration of enbosarm did not seem to be associated with an increased risk of adverse effects. Results of a phase II trial of another SARM, MK-0773, were published in 2013 (REF. 65) ; in this double blind, placebo-controlled trial involving 170 women with sarcopenia, lean body mass substantially increased in MK-0773-treated patients at 6 months, without evidence of androgenization. Physical performance showed a trend towards improvement over the follow-up period; however, this finding was not statistically significant. Several patients in the treatment group had elevated levels of transaminases but this clinical feature resolved on study discontinuation 65 .
Myostatin is an inhibitor of muscle growth and hence a potential target for preventing or reversing muscle loss; several studies have presented evidence for the potential benefits of targeting the myostatin pathway for improving muscle function. Findings from a 2015 study investigating a humanized monoclonal myostatin antibody that binds and neutralizes myostatin suggest that treatment with this antibody can increase lean mass and might also improve functional measures of muscle power 66 . In a phase II trial conducted on patients aged 75 years or older who had fallen in the past year, patients treated with the same humanized monoclonal myostatin antibody reported a higher muscle mass (0.43 kg, 95% CI 0.192-0.660) after 24 weeks when compared with the placebo group, in addition to demonstrating improvements in stair climbing time, chair rise with arms and fast gait speed 66 . These results follow previous approval for the use of this therapy in the treatment of inclusion body myositis (IBM); in patients with IBM a single dose of the antibody increased their 6 min walking distance by 52 m compared with placebo 67 . Myostatin signalling is mediated by the transmembrane kinase receptor activin receptor type IIB (ACTRIIB), a molecule that might also be a promising therapeutic target. ACTRIIB is highly expressed in mammalian skeletal muscle, and postnatal blockade of ACTRIIB signalling in mice leads to rapid and massive muscle hypertrophy 68 . One therapeutic approach for blocking ACTRIIB signalling involves the systemic delivery of a soluble recombinant form of the receptor that acts as a decoy, thus disrupting the interaction between the receptor and its ligands 68 . Having previously been trialled in patients with muscular dystrophy, which is characterized by progressive muscle weakening and wasting, a 2015 study of the effect of receptor blockade in wild-type mice demonstrated that blockade of ACTRIIB with a soluble receptor for 8 weeks increased absolute force-generating capacity and reduced mitochondrial function in glycolytic gastrocnemius muscle without compromising energy status during sustained activity 68 . This suggests that this agent might be considered for trial in sarcopenic patients in the future.
Preventive and therapeutic strategies are required in the management of sarcopenia. Marzetti et al. have previously reviewed this topic, and specifically considered targeting mitochondrial dysfunction to treat sarcopenia 69 , highlighting the potential challenges and risks of such a strategy, as well as suggesting possible study populations. They discuss safety considerations when designing such a trial; what outcome measures to consider, and the need for biomarkers; the optimal timing and duration of the intervention and the selection of a target population. Unfortunately, to date no such agent has become available for trial in a clinical setting. 
Conclusions
Due to ageing of the population, conditions that emerge later in life and that are associated with considerable morbidity and public health costs are of great consequence. Sarcopenia, which is linked to frailty, is perhaps one of the most important of these conditions and a strong research agenda has emerged to consider the aetiological factors that might prevent or retard the development or progression of sarcopenia. An understanding of the biology of ageing as applied to muscle might help us to identify those at risk of sarcopenia, and to identify potential therapeutic targets; hence, a partnership between basic biologists, the pharmaceutical industry and clinicians is critical. Given the substantial personal, societal and economic burdens associated with sarcopenia, it is essential that we identify ways to detect those at greatest risk and use strategies for lifestyle modification to retard or prevent muscle loss at a population level. However, many individuals are also likely to benefit from a tailored pharmacological approach, and although methodological challenges regarding how best to define the condition, and what outcome measure to consider, have delayed research into possible therapeutic options, promising pharmacological agents have nonetheless emerged. To date, these treatments have largely been hormone-based approaches (such as treatment with testosterone and SARMs) although new developments have seen the emergence of a promising monoclonal antibody to myostatin and ACTRIIB-blockade agents.
A particular challenge for clinicians who treat patients with sarcopenia is that even though diagnostic tools have been developed that are accurate and reliable in research settings, many are not easily applied in clinical practice, and simpler diagnostic criteria have instead been proposed [70] [71] [72] . The fact that, despite being positively correlated, loss of muscle strength often exceeds loss of muscle mass is of considerable relevance when considering approaches to defining sarcopenia and clinical outcomes for pharmacological trials. Analogous to bone mineral density and fracture risk, if preservation of functional performance is the goal of sarcopenia treatment, study designers should be cognizant of the clinical outcome of choice.
